Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:28:05 EDT Tue 09 Jun 2026
Enter Symbol
or Name
USA
CA



Q:REGN - REGENERON PHARMACEUTICALS INC - https://www.regeneron.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
REGN - Q1.8610.53·628.040.2611.34-24.11-3.81,259.2771,58428,911638.04  638.95  608.98821.11  494.42Jun 08Jun 0415 min RT 2¢

Recent Trades - Last 10 of 28911
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-06-04 07:00U:REGNNews ReleaseRegeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
2026-05-28 16:00U:REGNNews ReleaseRegeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
2026-05-22 07:00U:REGNNews ReleaseOtarmeni(TM) (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
2026-05-21 17:02U:REGNNews ReleaseLynozyfic(TM) (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
2026-05-18 07:00U:REGNNews ReleaseRegeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon(TM) Conjugates Across Multiple Therapeutic Areas
2026-05-15 20:20U:REGNNews ReleaseRegeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
2026-05-15 17:57U:REGNNews ReleaseUPDATE - Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
2026-05-15 16:28U:REGNNews ReleaseNext Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
2026-05-08 07:00U:REGNNews ReleaseRegeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
2026-05-07 08:45U:REGNNews ReleaseBiotech's Next Wave May Already be in Motion
2026-05-05 07:00U:REGNNews ReleaseDupixent(TM) (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
2026-04-29 06:30U:REGNNews ReleaseRegeneron Reports First Quarter 2026 Financial and Operating Results
2026-04-23 15:46U:REGNNews ReleaseRegeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
2026-04-23 12:40U:REGNNews ReleaseOtarmeni(TM) (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
2026-04-22 17:30U:REGNNews ReleaseDupixent(TM) (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
2026-04-21 10:30U:REGNNews ReleaseCemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
2026-04-20 16:05U:REGNNews ReleaseRegeneron Announces Investor Conference Presentations
2026-04-13 06:30U:REGNNews ReleaseRegeneron and Telix Announce Strategic Radiopharma Collaboration
2026-04-13 06:30U:REGNNews ReleaseTelix and Regeneron Announce Strategic Radiopharma Collaboration